RxDoctor Payments DataLook up a doctor →

Boqing Chen, MD

Pain Medicine · Metuchen, NJNPI 1649291410

Payments from drug & device makers

$6,935in general payments, 2019–2025

Across 259 payments — averaging $26.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Spinefrontier, Inc.$1K
  • Abbott$1K
  • Collegium Pharmaceutical, Inc.$648
  • Curonix LLC$581
  • Boston Scientific$398
  • Medtronic$351
  • plus $2K from 33 others

What the payments were for

  • Travel & lodging$1,83126%
  • Food & beverage$5,02472%
  • Education$801%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,935 in reported general payments places this provider in the 80th percentile of 256 pain medicine providers in New Jersey.

See all pain medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$816,484
Medicare patients
510
Services billed
19,102

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PercocetOxycodone Hcl/Acetaminophen12$49,390
OxycontinOxycodone Hcl37$17,015
Xtampza ErOxycodone Myristate18$14,655
Oxycodone Hcl627$13,040
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen397$10,125
Fentanyl72$7,350
Gabapentin346$3,951
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl17$1,976
Morphine Sulfate ErMorphine Sulfate63$1,958
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen68$1,654
Lidocaine16$1,585
Tramadol Hcl159$1,366
Cyclobenzaprine Hcl105$1,112
Pregabalin41$949
Morphine Sulfate16$890

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$648$14,65518 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 256 pain medicine providers in New Jersey.

Other pain medicine in Metuchen

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →